US FDA grants Priority Review to Roches Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer

Source :: Legal Monitor Worldwide. August 4, 2021
Publication Year :: 2021
Abstract: (GlobeNewswire) - Application is being reviewed under the US FDAs Real-Time Oncology Review pilot programme Based on results of the Phase III IMpower010 study, presented at ASCO, that showed adjuvant [...]

Subjects :: United States. Food and Drug Administration
Roche Holding AG
Cancer -- Adjuvant treatment
Biotechnology industry
Vemurafenib
Immunotherapy
Lung cancer, Non-small cell -- Care and treatment
Business, international
Law
Tecentriq (Medication)

Tools